Literature DB >> 23121914

The past, present and future of renin-angiotensin aldosterone system inhibition.

Robert J Mentz1, George L Bakris, Bernard Waeber, John J V McMurray, Mihai Gheorghiade, Luis M Ruilope, Aldo P Maggioni, Karl Swedberg, Ileana L Piña, Mona Fiuzat, Christopher M O'Connor, Faiez Zannad, Bertram Pitt.   

Abstract

The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trials; Heart failure; Hypertension; Myocardial infarction; Renin–angiotensin aldosterone system

Mesh：

Substances：

Year:  2012        PMID： 23121914      PMCID： PMC4145865          DOI： 10.1016/j.ijcard.2012.10.007

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


  127 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

Review 4.  Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Authors:  Z H Israili
Journal:  J Hum Hypertens       Date:  2000-04       Impact factor: 3.012

5.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.

Authors:  E Ambrosioni; C Borghi; B Magnani
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245

6.  Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Authors:  Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237

Review 7.  Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.

Authors:  A D Struthers
Journal:  J Card Fail       Date:  1996-03       Impact factor: 5.712

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

9.  Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.

Authors:  M de Gasparo; U Joss; H P Ramjoué; S E Whitebread; H Haenni; L Schenkel; C Kraehenbuehl; M Biollaz; J Grob; J Schmidlin
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  31 in total

Review 1.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

2.  ACE overexpression in myeloid cells increases oxidative metabolism and cellular ATP.

Authors:  Duo-Yao Cao; Weston R Spivia; Luciana C Veiras; Zakir Khan; Zhenzi Peng; Anthony E Jones; Ellen A Bernstein; Suguru Saito; Derick Okwan-Duodu; Sarah J Parker; Jorge F Giani; Ajit S Divakaruni; Jennifer E Van Eyk; Kenneth E Bernstein
Journal:  J Biol Chem       Date:  2019-12-23       Impact factor: 5.157

3.  Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril.

Authors:  G H Oliveira-Paula; R Lacchini; V Fontana; P S Silva; C Biagi; Jose E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2015-05-24       Impact factor: 2.953

4.  [Hyperkalemia : what can we expect from new potassium-lowering drugs?].

Authors:  R Schmitt
Journal:  Internist (Berl)       Date:  2015-07       Impact factor: 0.743

Review 5.  Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.

Authors:  Peter J Fuller
Journal:  Clin Biochem Rev       Date:  2013-11

Review 6.  Angiotensin-converting enzyme in innate and adaptive immunity.

Authors:  Kenneth E Bernstein; Zakir Khan; Jorge F Giani; Duo-Yao Cao; Ellen A Bernstein; Xiao Z Shen
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

Review 7.  New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.

Authors:  Anjay Rastogi; Farid Arman; Setareh Alipourfetrati
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

8.  Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure.

Authors:  Katelee Barrett Mueller; Shawn B Bender; Kwangseok Hong; Yan Yang; Mark Aronovitz; Frederic Jaisser; Michael A Hill; Iris Z Jaffe
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

9.  The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient.

Authors:  Graziano Riccioni
Journal:  Ther Adv Endocrinol Metab       Date:  2013-10       Impact factor: 3.565

Review 10.  COVID-19 and male reproductive system: pathogenic features and possible mechanisms.

Authors:  Arash Ardestani Zadeh; Davood Arab
Journal:  J Mol Histol       Date:  2021-07-07       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.